SCHEMBL4919059

SCHEMBL4919059

CCC/C=C\CC/C=C/C=C/C(=O)NCC(C)C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 12/20 0.77
CNR1 P21554 8/20 0.77
FAAH O00519 4/20 0.77
PPARG P37231 2/20 0.74
PPARD Q03181 2/20 0.74
PPARA Q07869 2/20 0.74
SOAT1 P35610 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4919073 1.00 CNR2 (0.77) CNR2CNR1FAAHPPARGPPARD
SCHEMBL26125952 0.98 CNR2 (0.79) CNR2CNR1FAAHPPARGPPARD
SCHEMBL29498103 0.95 CNR2 (0.75) CNR2CNR1FAAHPPARGPPARD
SCHEMBL1872998 0.95 CNR2 (0.75) CNR2CNR1FAAHPPARGPPARD
SCHEMBL29483345 0.95 CNR2 (0.75) CNR2CNR1FAAHPPARGPPARD
SCHEMBL6055029 0.95 CNR2 (0.75) CNR2CNR1FAAHPPARGPPARD
SCHEMBL4312207 0.95 CNR2 (0.75) CNR2CNR1FAAHPPARGPPARD
SCHEMBL6055028 0.95 CNR2 (0.75) CNR2CNR1FAAHPPARGPPARD
SCHEMBL1030318 0.95 CNR2 (0.75) CNR2CNR1FAAHPPARGPPARD
SCHEMBL1028869 0.95 CNR2 (0.75) CNR2CNR1FAAHPPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150079198-A1 METHOD AND NUTRITIONAL SUPPLEMENT FOR ENHANCING WEIGHT GAIN OF A MAMMAL SUPRAGENIX LLC 2015-03-19 US claimed
US-9226906-B2 Method and nutritional supplement for enhancing weight gain of a mammal Supragenix, LLC (US) 2016-01-05 US disclosed
US-9205121-B2 Echinacea formulation Integria Healthcare (Australia) PTY LTD (AU) 2015-12-08 US disclosed
US-20150079198-A1 METHOD AND NUTRITIONAL SUPPLEMENT FOR ENHANCING WEIGHT GAIN OF A MAMMAL SUPRAGENIX LLC 2015-03-19 US disclosed
US-20110059194-A1 ECHINACEA FORMULATION MEDIHERB HOLDINGS LTD. (AU) 2011-03-10 US disclosed
US-20080124408-A1 Echinacea Formulation MEDIHERB HOLDINGS LTD. (AU) 2008-05-29 US disclosed
WO-2006002493-A1 AN ECHINACEA FORMULATION MEDIHERB HOLDINGS LTD (AU) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080124408-A1 Echinacea Formulation FAAH2, ABCC8, FAAH CNR2 4/4885CNR1 18/4885FAAH 3/4885
US-20110059194-A1 ECHINACEA FORMULATION FAAH2, ABCC8, FAAH CNR2 4/4885CNR1 18/4885FAAH 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.